Intracoronary Transplantation of Non-Expanded Peripheral Blood-Derived Mononuclear Cells Promotes Improvement of Cardiac Function in Patients With Acute Myocardial Infarction

Abstract

Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp 1. We would like to rewrite a statement in the Methods and Results section of the Abstract.Original Statement (p.1199, Abstract, Lines 5-10):After successful percutaneous coronary intervention (PCI) for a ST-elevation AMI with occlusion of proximal left anterior descending coronary artery within 24 h, patients were assigned to either a control group or the PBMNC group that received intracoronary infusion of PBMNCs within 5 days after PCI. PBMNCs were obtained from patients by COBE spectra-apheresis and concentrated to 10 ml, 3.3 ml of which was infused via over-the-wire catheter. The primary endpoint was the global left ventricular ejection fraction (LVEF) change from baseline to 6 months' follow-up.Corrected Statement: After successful percutaneous coronary intervention (PCI) for ST-elevation AMI with occlusion of proximal left anterior descending coronary artery within 24 h, patients received an intracoronary infusion of PBMNCs within 5 days after PCI (PBMNC group). PBMNCs were obtained from the patients by COBE spectra-apheresis and concentrated to 10 ml, 3.3 ml of which was infused via over-the-wire catheter. The global left ventricular ejection fraction (LVEF) change from baseline to 6 months' followup in the PBMNC group was compared with that of a control group that underwent standard PCI for similar AMI.2. We would like to correct the paragraph on the study design in the Patients and Study Protocol in the Methods section as below, in order to avoid misinterpretation of the control patients.

From bench to bedside, work in cell-based myocardial regeneration therapy

“…The TOPCARE-AMI Trial in 2004 for AMI patients without a control showed significant improvement in the LVEF, an attenuation of LV dilatation, and reduced infarct size at the one-year follow-up [50]. Tatsumi et al performed an open-label, nonrandomized, controlled clinical trial for AMI patients treated with CPC implantation without using G-CSF and cell expansion, and revealed a significant increase in the LVEF and regional systolic performance at 6 months without any adverse clinical events [61]. The first randomized, double blind, and placebo-controlled study on CPC transplantation demonstrated an improvement in coronary flow reserve, decline in the number of hibernating segments, and an increase in LVEF at 3 months after transplantation, indicating that CPC transplantation was effective for OMI patients [62].…”

Revisiting cardiovascular regeneration with bone marrow‐derived angiogenic and vasculogenic cells

“…Particularly, BM-derived endothelial progenitor cells (EPCs) have been studied by many research groups and have shown therapeutic potentials in animal models of myocardial and peripheral vascular ischaemia (Kalka et al, 2000;Murohara et al, 2000;Schatteman et al, 2000;Kawamoto et al, 2001;Kocher et al, 2001;Iwasaki et al, 2006;Jeong et al, 2009). Moreover, a series of clinical trials using EPCs or similar BM cells has shown therapeutic benefits to treat postmyocardial infarction (MI) cardiac dysfunction and critical limb ischaemia (Assmus et al, 2002;Bartunek et al, 2005;Boyle et al, 2006;Schaefer et al, 2006;Li et al, 2007;Losordo et al, 2007;Stamm et al, 2007;Tatsumi et al, 2007;Hare et al, 2009;Burt et al, 2010;Kuroda et al, 2011;Miettinen et al, 2010). On the other hand, other studies have revealed conflicting results with regard to the effects of BM-derived mononuclear cells (MNCs) on myocardial ischaemia in a similar subset of patients (Janssens et al, 2006;Lunde et al, 2006;Meyer et al, 2006;Penicka et al, 2007).…”